Home/Pipeline/TNG908

TNG908

MTAP-deleted solid tumors

Phase 1/2Active

Key Facts

Indication
MTAP-deleted solid tumors
Phase
Phase 1/2
Status
Active
Company

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotech focused on discovering and developing precision oncology medicines based on synthetic lethality. The company has built a robust pipeline with multiple clinical-stage assets, including PRMT5 and CoREST inhibitors, targeting cancers with specific genetic alterations like MTAP deletion and STK11 mutations. Its integrated discovery platform combines CRISPR-based functional genomics with patient-derived data to systematically identify novel drug targets, positioning it at the forefront of next-generation cancer therapeutics.

View full company profile

Therapeutic Areas

Other MTAP-deleted solid tumors Drugs

DrugCompanyPhase
TNG462Tango TherapeuticsPhase 1/2
IDE397IDEAYA BiosciencesPhase 1/2